Comparative Pharmacology
Head-to-head clinical analysis: DURADYNE DHC versus XARTEMIS XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURADYNE DHC versus XARTEMIS XR.
DURADYNE DHC vs XARTEMIS XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DURADYNE DHC contains dihydrocodeine, an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception and response.
XARTEMIS XR is a combination of oxycodone (a full mu-opioid receptor agonist) and acetaminophen (a centrally acting analgesic with antipyretic properties via cyclooxygenase inhibition).
1 tablet (10 mg hydrocodone/300 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
1 tablet (oxycodone 7.5 mg / acetaminophen 325 mg) orally every 12 hours; maximum 2 tablets per day.
None Documented
None Documented
Terminal elimination half-life of dihydrocodeine is approximately 4 hours; clinically relevant for dosing interval of 4-6 hours.
Oxycodone: 5.3-6.6 hours (immediate-release), extended-release formulation shows prolonged absorption with apparent half-life ~7.2-9.6 hours; naloxone: 2-3 hours.
Primarily renal excretion of metabolites; ~90% excreted in urine as glucuronide conjugates and morphine; ~10% in feces via bile.
Renal: oxycodone and metabolites ~8.8% free oxycodone, ~8.8% noroxycodone, ~33% conjugated metabolites; naloxone: extensive hepatic metabolism, <1% excreted unchanged in urine. Fecal: naloxone metabolites ~17%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic